Document is current
Any future updates will be listed below
-
Authors
Costa-Verdera, Helena
Gargaro, Marco
Cagin, Umut
Manni, Giorgia
Scalisi, Giulia
Veron, Philippe
Silva Barcelos, Estevão Carlos
Pieroni, Benedetta
Mencarelli, Giulia
Ricciuti, Doriana
Nemazanyy, Ivan
Sanatine, Peggy
van Wittenberghe, Laetitia
Laforêt, Pascal
Gross, David-Alexandre
Ronzitti, Giuseppe
Fallarino, Francesca
Mingozzi, Federico https://orcid.org/0009-0002-9658-6466
-
Funding
Funding for this research was provided by:
Fondazione Telethon (GMR22T1081)
Associazione Italiana per la Ricerca sul Cancro (30318)
European Research Council (101078646)
- License Information
-
More Information
Article History
Received: 20 August 2025
Revised: 18 December 2025
Accepted: 11 February 2026
First Online: 16 March 2026
Declarations
:
: Federico Mingozzi and Giuseppe Ronzitti are inventors in patents applications concerning the treatment of Pompe disease by AAV licensed to Spark Therapeutics (WO2018046774, WO2018046775, WO2018046775). Federico Mingozzi is a former employee of Spark Therapeutics. Helena Costa-Verdera is a current employee of Spark Therapeutics. All other authors have no relevant interests to disclose.
